Sato Pharmaceutical Co., Ltd.
http://www.sato-pharmaceutical.com/us/usa/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sato Pharmaceutical Co., Ltd.
Verrica's Phase III Success Paves Way For Filing Of New Cantharidin Formulation VP-102
After reporting positive pivotal data for VP-102 in the contagious skin disease molluscum, Verrica is looking forward to a 2020 launch, with plans to price for broad access.
Pipeline Watch: Top-Line Data For Reslizumab, Erenumab And Biosimilar Rituximab
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Deals Shaping The Medical Industry, November 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
OTC Recalls: Children's Allergy Tablets, Eye Care Products
Standard Homeopathic's recent recall of its Hyland’s teething tablets was designated class I, indicating a reasonable probability of serious adverse health consequences or death, FDA notes in May 31 update to its recalls database.
Company Information
- Industry
-
Pharmaceuticals
- OTC, Consumer